VERACODE
28.7.2022 08:52:11 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform in Europe. Companies can now secure their software across the entire software development lifecycle (SDLC) with the added capabilities of dynamic analysis and API scanning, complementing Veracode’s static analysis, software composition analysis and manual penetration testing tools. The Veracode European Region , a cloud-based instance, allows customer data to stay resident in the EU to meet policy requirements for cloud computing.
Demand for a SaaS-based software security solution that supports data residency has never been greater. With a 20x increase * in security scanning cadence over the past decade, organisations are now testing apps for flaws more thoroughly than ever. Many are shifting further left and combining static, dynamic, and software composition analysis to gain a comprehensive view of risk and compliance to policies.
Veracode’s EMEA Chief Technology Officer, John Smith, said, “The European market has a growing need to consolidate and automate application security, while meeting stringent data residency requirements. The options for achieving this at scale are limited and complex: on-premise solutions require a large, upfront investment and frequent upgrades, while other SaaS platforms are often a pared-down version of existing on-premise products. Veracode’s cloud-native platform helps customers keep costs down and increase efficiencies by integrating multiple software security tools into one easy-to-use solution that also monitors policy compliance.”
Based in Frankfurt, Germany, the Veracode European Region is a cloud-based instance that offers customers in EMEA a broad suite of solutions as part of its unified Continuous Software Security Platform, which bridges the gap between security and development teams. Dynamic analysis and API scanning are the latest capabilities to be made available in the market. The integrated platform is unique since it gives customers a “single pane of glass” view of security posture across their entire SDLC.
Seamlessly embedded into the environments where developers work, Veracode creates a frictionless experience for developers to code securely without compromising speed of delivery. This is paramount to help businesses keep pace with accelerating deployment times, as well as to provide a comprehensive view of risk, remediation guidance, peer benchmarking, and rich analytics throughout the development pipeline.
Powered by nearly two decades of aggregate data, the cloud-native platform continually finetunes itself to improve accuracy, yielding impressively low false-positive rates. It also streamlines workflows by running daily updates of the vulnerability database, so customers are immediately apprised of any potential threats.
A customer of Veracode, a European commerce body, said, “The privacy and protection of our customers is our highest priority, so we need to be confident in our software security programme. Veracode gives us this assurance with a fully SaaS platform that is resident in the EU. Initially, we needed an automated dynamic analysis product that could crawl our applications at scale but wanted to avoid the pain of amassing several disparate tools over time. With Veracode, we are safe in the knowledge that we can leverage multiple solutions in one place as we continue to shift security further left.”
Find out more about Veracode’s European Region here .
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com , on the Veracode blog and on Twitter .
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005607/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release
Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our
Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release
H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE
Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan
Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release
Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
